Article Details
Retrieved on: 2018-01-24 03:41:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Ultragenyx Pharmaceutical, a Novato-based biotech company that develops drugs for rare and ultra-rare genetic diseases, priced shares on Jan. 23 for a public stock offering that could raise nearly $250 million in capital. On Tuesday the company priced each share at $57 for the offering of 4.4 million ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here